Journal Home
Search for

Volume 31, Issue 11, Pages 2088-2092 (November 2005)


View previous. 32 of 60 View next.

Blue-light filtering intraocular lens in patients with diabetes: Contrast sensitivity and chromatic discrimination

Antonio Rodríguez-Galietero, MD, PhD, FEBOCorresponding Author Informationemail address, Robert Montés-Micó, PhD, Gonzalo Muñoz, MD, PhD, FEBO, Cesar Albarrán-Diego, OD

Accepted 5 April 2005.

Purpose

To evaluate potential changes in contrast sensitivity and color discrimination in diabetic patients who had cataract surgery and implantation of the blue-light filtering AcrySof Natural (SN60AT) intraocular lens (IOL) compared with an ultraviolet-only filtering (AcrySof SA60AT) IOL.

Setting

Refractive Surgery Unit, Hospital NISA Valencia al Mar, Valencia, Spain.

Methods

Forty-four eyes of 22 diabetic patients were enrolled in a blue-light filtering fellow-eye control study. Patients received yellow-tinted IOLs (AcrySof Natural) in 1 eye and non–yellow-tinted IOLs (AcrySof SA60AT) in the fellow eye. Three months after surgery, monocular contrast sensitivity function was measured with the CSV 1000-E contrast sensitivity chart at distance and color discrimination was tested with the Farnsworth-Munsell 100-hue test.

Results

Eyes implanted with the blue-light filtering IOLs showed better contrast sensitivity values than fellow eyes implanted with non–yellow-tinted IOLs (P<.05). The blue-light filtering IOL did not modify chromatic discrimination compared with the non–yellow-tinted IOL (P = .62). In the blue–yellow axis discrimination study, the eyes implanted with the AcrySof Natural IOL had statistically significant better color vision (P = .008).

Conclusions

In diabetic patients, the AcrySof Natural IOL provides better contrast sensitivity than the AcrySof SA60AT. The blue-light filter of the AcrySof Natural IOL did not cause chromatic discrimination defects based on total error scores and improved color vision in the blue–yellow chromatic axis in diabetic patients.

From the Refractive Surgery Unit (Rodríguez-Galietero, Montés-Micó, Muñoz, Albarrán-Diego), Hospital NISA Valencia al Mar, Valencia, and VISSUM Ophthalmologic Institute of Alicante (Montés-Micó, Muñoz), Alicante, Spain

Corresponding Author InformationReprint requests to Antonio Rodríguez-Galietero, MD, PhD, FEBO, Urbanización Villas de Rocafort (villa 16), 46111 Rocafort, Valencia, Spain.

 No author has a financial and proprietary interest in any material or method mentioned.

PII: S0886-3350(05)00676-0

doi:10.1016/j.jcrs.2005.04.029


View previous. 32 of 60 View next.